Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Mirati Therapeutics stock | $190.29

Learn how to easily invest in Mirati Therapeutics stock.

Mirati Therapeutics Inc is a biotechnology business based in the US. Mirati Therapeutics shares (MRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Mirati Therapeutics employs 199 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Mirati Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MRTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Mirati Therapeutics stock price (NASDAQ: MRTX)

Use our graph to track the performance of MRTX stocks over time.

Mirati Therapeutics shares at a glance

Information last updated 2021-10-17.
Latest market close$190.29
52-week range$131.47 - $249.42
50-day moving average $170.59
200-day moving average $161.56
Wall St. target price$222.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-10.04

Buy Mirati Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Mirati Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Mirati Therapeutics price performance over time

Historical closes compared with the close of $190.29 from 2021-10-22

1 week (2021-10-15) 6.74%
1 month (2021-09-24) 14.38%
3 months (2021-07-23) 21.10%
6 months (2021-04-23) 22.25%
1 year (2020-10-23) 5.60%
2 years (2019-10-24) 149.76%
3 years (2018-10-24) 494.66%
5 years (2016-10-24) 3,490.38%

Mirati Therapeutics financials

Revenue TTM $13.1 million
Gross profit TTM $13.4 million
Return on assets TTM -30.43%
Return on equity TTM -56.58%
Profit margin 0%
Book value $21.88
Market capitalisation $9.2 billion

TTM: trailing 12 months

Shorting Mirati Therapeutics shares

There are currently 4.0 million Mirati Therapeutics shares held short by investors – that's known as Mirati Therapeutics's "short interest". This figure is 20.2% up from 3.3 million last month.

There are a few different ways that this level of interest in shorting Mirati Therapeutics shares can be evaluated.

Mirati Therapeutics's "short interest ratio" (SIR)

Mirati Therapeutics's "short interest ratio" (SIR) is the quantity of Mirati Therapeutics shares currently shorted divided by the average quantity of Mirati Therapeutics shares traded daily (recently around 573623.85714286). Mirati Therapeutics's SIR currently stands at 7. In other words for every 100,000 Mirati Therapeutics shares traded daily on the market, roughly 7000 shares are currently held short.

However Mirati Therapeutics's short interest can also be evaluated against the total number of Mirati Therapeutics shares, or, against the total number of tradable Mirati Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Mirati Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Mirati Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.1164% of the tradable shares (for every 100,000 tradable Mirati Therapeutics shares, roughly 116 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Mirati Therapeutics.

Find out more about how you can short Mirati Therapeutics stock.

Mirati Therapeutics share dividends

We're not expecting Mirati Therapeutics to pay a dividend over the next 12 months.

Have Mirati Therapeutics's shares ever split?

Mirati Therapeutics's shares were split on a 1:50 basis on 2 July 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Mirati Therapeutics shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Mirati Therapeutics shares which in turn could have impacted Mirati Therapeutics's share price.

Mirati Therapeutics share price volatility

Over the last 12 months, Mirati Therapeutics's shares have ranged in value from as little as $131.47 up to $249.42. A popular way to gauge a stock's volatility is its "beta".

MRTX.US volatility(beta: 1.38)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mirati Therapeutics's is 1.3794. This would suggest that Mirati Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Mirati Therapeutics overview

Mirati Therapeutics, Inc. , a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Frequently asked questions

What percentage of Mirati Therapeutics is owned by insiders or institutions?
Currently 1.384% of Mirati Therapeutics shares are held by insiders and 104.063% by institutions.
How many people work for Mirati Therapeutics?
Latest data suggests 199 work at Mirati Therapeutics.
When does the fiscal year end for Mirati Therapeutics?
Mirati Therapeutics's fiscal year ends in December.
Where is Mirati Therapeutics based?
Mirati Therapeutics's address is: 3545 Cray Court, San Diego, CA, United States, 92121
What is Mirati Therapeutics's ISIN number?
Mirati Therapeutics's international securities identification number is: US60468T1051
What is Mirati Therapeutics's CUSIP number?
Mirati Therapeutics's Committee on Uniform Securities Identification Procedures number is: 60468T105

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site